Van Cleef Asset Management Inc Has $2.14 Million Position in Eli Lilly and Company (NYSE:LLY)

Van Cleef Asset Management Inc boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 18.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,676 shares of the company’s stock after acquiring an additional 575 shares during the period. Van Cleef Asset Management Inc’s holdings in Eli Lilly and Company were worth $2,143,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. JGP Wealth Management LLC lifted its stake in Eli Lilly and Company by 0.9% in the fourth quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock valued at $1,074,000 after buying an additional 16 shares during the period. Walkner Condon Financial Advisors LLC raised its position in shares of Eli Lilly and Company by 2.8% in the 3rd quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock valued at $334,000 after acquiring an additional 17 shares during the period. Patton Albertson Miller Group LLC boosted its stake in Eli Lilly and Company by 2.8% during the 3rd quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock worth $335,000 after acquiring an additional 17 shares during the last quarter. Valley Wealth Managers Inc. boosted its stake in Eli Lilly and Company by 1.3% during the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock worth $688,000 after acquiring an additional 17 shares during the last quarter. Finally, Sandy Cove Advisors LLC grew its holdings in Eli Lilly and Company by 0.8% during the fourth quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company’s stock valued at $1,307,000 after purchasing an additional 17 shares during the period. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. BMO Capital Markets increased their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Barclays boosted their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Finally, Citigroup boosted their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Stock Performance

NYSE LLY traded down $7.33 on Thursday, hitting $724.87. 2,597,583 shares of the stock were exchanged, compared to its average volume of 3,034,002. The company has a market capitalization of $688.74 billion, a PE ratio of 124.61, a P/E/G ratio of 1.63 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The business’s fifty day moving average is $763.40 and its 200 day moving average is $664.52. Eli Lilly and Company has a 52 week low of $370.68 and a 52 week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period in the previous year, the business earned $2.09 EPS. Eli Lilly and Company’s revenue for the quarter was up 28.1% compared to the same quarter last year. Research analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.